Alzheimer’s drug shows promising results: Biogen
Biotechnology company Biogen released clinical trial data it said represented a significant reduction in amyloid plaques in the brains of people affected by Alzheimer’s disease. The findings were presented to the Alzheimer’s Association International Conference. Biogen’s PRIME study is an ongoing Phase 1b randomized, double-blind, placebo-controlled, multiple-dose study evaluating the safety, tolerability and clinical effects ...click here to read more
